2009
DOI: 10.1053/j.seminoncol.2008.10.003
|View full text |Cite
|
Sign up to set email alerts
|

Neuroendocrine Carcinoma of Unknown Primary Site

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
69
0
7

Year Published

2011
2011
2021
2021

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 98 publications
(77 citation statements)
references
References 46 publications
1
69
0
7
Order By: Relevance
“…Patients with small cell carcinoma at a metastatic site are considered for systemic therapy at the time of diagnosis. Although the optimum regimen is undefined, a platinum/etoposide-based regimen is currently used [7]. In this case report, we describe an uncommon case of inguinal lymph node small cell metastasis of unknown origin, accompanied by multiple sites of involvement.…”
Section: Introductionmentioning
confidence: 92%
“…Patients with small cell carcinoma at a metastatic site are considered for systemic therapy at the time of diagnosis. Although the optimum regimen is undefined, a platinum/etoposide-based regimen is currently used [7]. In this case report, we describe an uncommon case of inguinal lymph node small cell metastasis of unknown origin, accompanied by multiple sites of involvement.…”
Section: Introductionmentioning
confidence: 92%
“…Even in cases, where it is unable to detect the primary site, it provides useful information for guiding clinical management of such patients. Tumor grade/differentiation status currently is an important determinant of the personalized management of these patients (8).…”
Section: Discussionmentioning
confidence: 99%
“…Often the primary site is small, occult with possibility of multiple and variable primary sites which makes their evaluation difficult (7). Patients with metastatic NETs and unknown primary site (CUP-NET) constitute less than 5% of overall carcinomas of unknown primary (CUP) population (8). However, they constitute 10-13% of total NET study populations (9,10).…”
Section: Introductionmentioning
confidence: 99%
“…Squamous cell carcinomas are usually negative for cytokeratins 7 and 20 -two cytokeratins that are often expressed by adenocarcinomas. Among others, determination of neuroendocrine lineage is achieved by the detection of the very specifi c antigens chromogranin A and synaptophysin as well as CD56 (neural cell adhesion molecule, N-CAM), which is very sensitive but less specifi c than the two aforementioned markers [ 17 ]. A fourth antigen indicating neuroendocrine differentiation, NSE (neuron-specifi c enolase), is a very sensitive but even less specifi c marker, so that its diagnostic utility and signifi cance are rather limited.…”
Section: Algorithms For Carcinoma Subtypingmentioning
confidence: 99%